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Evaluating the pathogenicity of a variant is challenging given the plethora of types of genetic evidence that laboratories consider.
Deciding how to weigh each type of evidence is difficult, and standards have been needed. In 2015, the American College of Medical
Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines for the assessment of variants
in genes associated with Mendelian diseases. Nine molecular diagnostic laboratories involved in the Clinical Sequencing Exploratory
Research (CSER) consortium piloted these guidelines on 99 variants spanning all categories (pathogenic, likely pathogenic, uncertain
significance, likely benign, and benign). Nine variants were distributed to all laboratories, and the remaining 90 were evaluated by three
laboratories. The laboratories classified each variant by using both the laboratory’s ownmethod and the ACMG-AMP criteria. The agree-
ment between the two methods used within laboratories was high (K-alpha ¼ 0.91) with 79% concordance. However, there was only
34% concordance for either classification system across laboratories. After consensus discussions and detailed review of the ACMG-
AMP criteria, concordance increased to 71%. Causes of initial discordance in ACMG-AMP classifications were identified, and recommen-
dations on clarification and increased specification of the ACMG-AMP criteria were made. In summary, although an initial pilot of the
ACMG-AMP guidelines did not lead to increased concordance in variant interpretation, comparing variant interpretations to identify
differences and having a common framework to facilitate resolution of those differences were beneficial for improving agreement,
allowing iterative movement toward increased reporting consistency for variants in genes associated with monogenic disease.Introduction
The assessment of pathogenicity of genetic variation is one
of the more complex and challenging tasks in the field of
clinical genetics. It is now clear that enormous genetic vari-
ation exists in the human population. Most of this varia-
tion, including very rare variants, is unlikely to contribute
substantively to human disease. For example, a typical
genome sequence and reference genome have about 3.5
million differences, of which 0.6 million are rare or
novel.1 As such, the challenge of interpreting the clinical
significance of this variation is well recognized as a barrier
to furthering genomic medicine.2,3
We have previously reported both inconsistencies across
laboratories in the classification of Mendelian-disease var-
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 2016 American Society of Human Genetics.classification system, whereby reviewers showed a bias to-
ward overestimating pathogenicity.4 Furthermore, recent
analyses of variant classifications in ClinVar showed that
for the 11% (12,895/118,169) of variants with two or
more submitters, interpretations differed in 17% (2,229/
12,895).3 Inconsistency of the classification of variants
across professional genetics laboratories has been reported
elsewhere.5 These data highlight the need for a more sys-
tematic and transparent approach to variant classification.
Laboratories performing and reporting the results of
clinical genetic testing are now tasked with considering
a plethora of types of genetic evidence, some applicable
to all genes and others specific to individual genes and
diseases. To date, laboratories have developed their own
methods of variant assessment because the prior Amer-
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variant-reporting guidelines did not address the weighting
of evidence for variant classification.6 Some laboratories
assign points to types of evidence and generate a score,7
and others define specific combinations of evidence that
allow them to arrive at each classification category8 or
use a Bayesian framework to combine data types into a
likelihood ratio.9 Still others have simply relied on expert
judgment of the individual body of evidence on each
variant to make a decision.
Deciding how to categorize and weigh each type of
evidence is challenging, and guidance has been needed.
Making the task even more challenging is that the true
pathogenicity is not known for most variants, and it is
therefore difficult to validate approaches to variant assess-
ment, particularly for addressing variants that have limited
evidence. However, combining the collective experience of
experts in the community to begin to build a more system-
atic and transparent approach to variant classification is
essential, and this has led the ACMG and Association for
Molecular Pathology (AMP) to develop a framework for ev-
idence evaluation. The initial framework was published in
early 201510 and focused on variants in genes associated
with Mendelian disease.
TheACMG-AMPguidelines defined 28 criteria (eachwith
an assigned code) that address evidence such as population
data, case-control analyses, functional data, computational
predictions, allelic data, segregation studies, and de novo
observations. Each code is assigned a weight (stand-alone,
very strong, strong, moderate, or supporting) and direction
(benign or pathogenic), and then rules guide users to
combine these evidence codes to arrive at one of five classi-
fications: pathogenic (P), likely pathogenic (LP), variant of
uncertain significance (VUS), likely benign (LB), or benign
(B). In some cases, the strength of individual criteria can
be modified at the discretion of the curator, and the overall
classification can be modified with expert judgment. As an
example, a minor allele frequency (MAF) greater than the
disease prevalence but less than 5% is coded benign strong
(BS1); this is considered strong evidence against pathoge-
nicity for a highly penetrant monogenic disorder and
supports a LB classification when it is combined with at
least one supporting line of evidence against pathogenicity
(BP1–BP6). If BS1 is combined with another strong line of
evidence against pathogenicity (BS2–BS4), this supports a
B classification. Conversely, a variant predicted to be null
(PVS1) would be classified as LP if it is absent from popula-
tion databases (PM2) or P if it is observed to be de novowith
confirmed paternity and maternity (PS2). If not enough
lines of evidence are invoked to classify a variant as P, LP,
LB, or B, or there are valid but contradictory lines of evi-
dence, a variant is interpreted as a VUS.
We set out to evaluate how the ACMG-AMP guidelines
compare to individual laboratory approaches to variant clas-
sification and explore the variance in the use and interpreta-
tion of the pathogenicity criteria. Nine laboratories partici-
pating in the Clinical Sequencing Exploratory Research
(CSER) consortium evaluated the use of the new ACMG-1068 The American Journal of Human Genetics 98, 1067–1076, JuneAMP guidelines and in-house interpretations to assess in-
ter-laboratory concordanceby eithermethodof variant clas-
sification. Our goals were to evaluate consistency of the use
of the ACMG-AMP codes and subsequent pathogenicity
classification. Further, we used these criteria to analyze the
basis for discordance and sought to reconcile differing im-
plementations with an eye to guidance clarification.Material and Methods
CSER is a National Human Genome Research Institute (NHGRI)-
and National Cancer Institute (NCI)-funded consortium exploring
the clinical use of genomic sequencing, developing best practices,
and identifying obstacles to implementation. It is composed of
nine clinical U-award sites focusing on all aspects of clinical
sequencing, the ClinSeq project,11 and nine R-award sites focusing
on ethical, legal, and social implications. Eight of the nine
clinical U-award sites and ClinSeq participated in this exercise.
These included laboratories performing exome and/or genome
sequencing for the following projects: BASIC3 (Baylor College of
Medicine, Houston), PediSeq (Children’s Hospital of Philadelphia),
CanSeq (Dana FarberCancer Institute, Boston),HudsonAlpha Insti-
tute for Biotechnology, MedSeq (Brigham and Women’s Hospital
and Partners Healthcare, Boston), NextGen (Oregon Health Sci-
ences University, Portland), NCGENES (University of North Car-
olina, ChapelHill), andNEXTMedicine (University ofWashington,
Seattle). Eight of the nine sites were accredited by the Clinical
Laboratory Improvement Amendments (CLIA).
Selection and Classification of Variants
Each site nominated 11 variants identified in their sequencing
projects for this exercise. Submitted variants were single-nucleo-
tide substitutions or small indels (<22 bp) in genes thought to
be associated with Mendelian disease. Each site was instructed to
provide a range of variants in each classification category with
varying degrees of difficulty. Accepted classifications were B, LB,
VUS, LP, and P. Each variant submission also included whether it
was identified as a diagnostic result or an incidental finding. Any
internal evidence that the submitting laboratory used to classify
the variant—for example, the phenotype and family history of
the proband or whether parental testing identified the variant as
de novo—was also provided to all laboratories. Nine variants
(two P, two LP, two VUS, two LB, and one B) were selected for dis-
tribution to all laboratories without the submitting laboratory’s
classification; half were identified as incidental findings, half
were identified as diagnostic findings, and one was from a carrier
screen. The remaining 90 variants were randomly distributed to
at least two other laboratories, enabling classifications from at least
three laboratories for each variant. Each laboratory was asked to
classify the pathogenicity by applying both their internal process
and then the ACMG-AMP system. They were asked to document
which ACMG-AMP criteria were invoked for the ACMG-AMP clas-
sification and note whether they found the classification of each
variant difficult, moderate, or easy. Time taken for categorizing
the variant was requested but not consistently recorded.
Application of Automated Tool for Calculation of
Overall Classification from Evidence Codes
In order to assess whether ACMG-AMP evidence codes were
combined appropriately by the variant curator, we developed a2, 2016
pathogenicity calculator that combines the provided codes to
generate a final classification. We used this calculator to compare
thecalculatedACMG-AMPclassificationbasedon tabulating the ev-
idence codes provided by the laboratory with the final ACMG-AMP
classificationsubmittedbythe laboratory.Weshared thesedatawith
sites for consideration during consensus discussions and manually
verified the results to identifywhichdiscrepanciesweredue to errors
by the submitting laboratory andwhichwere due to the use of judg-
ment in overruling the ACMG-AMP classification.Analysis of Intra- and Inter-laboratory Concordance
Descriptive statistics summarized the intra-laboratory classification
concordance between the ACMG-AMP system and the laboratory’s
own process and the inter-laboratory concordance both for each
laboratory’s own process and for the ACMG-AMP system across
laboratories. Additionally, we quantified the level of agreement.
To do this, we considered the five-tier classification system in the
following order—B, LB, VUS, LP, and P—and defined a one-step
level of disagreement to be a range of classifications from one cate-
gory to the next ordered category (e.g., from VUS to LP or LP to P);
themaximum level included four steps (i.e., B to P). In addition,we
tracked disagreements that were more likely to lead to medical-
management differences (P or LP versus any of VUS, LB, and B)
and disagreements less likely to affect clinical decision making
(e.g., VUS versus LB or B, or confidence differences, such as B versus
LB or P versus LP). To quantify the overall level of absolute agree-
ment onACMG-AMPand laboratory criteriawithin sites and agree-
ment between sites using ACMG-AMP or laboratory criteria, we
calculated Krippendorff’s alpha (K-alpha); ranging from 0 to 1,
this generalizedmeasure of absolute agreement corrects for chance
responding and can handle any number of raters, scale ofmeasure-
ment, andmissingdata. Because it focusesondisagreement, it over-
comes many of the weaknesses associated with other agreement
measures, such as Cohen’s kappa.12–16 In general, values of 0.80
and above are considered evidence of good agreement.14 We also
calculated 95% confidence intervals (CIs) for K-alpha by using
bootstrapping with 20,000 replications.17
Two variants were excluded from the quantitative analyses and
are not represented in Figures 1A and 1B; however, they are
represented in the overall concordance shown in Figures 1C
and 2. One variant was a low-penetrance allele (c.3920T>A
[p.Ile1307Lys] [GenBank: NM_001127510.2] in APC [MIM:
611731]) for which several laboratories did not assign an ACMG-
AMP classification, and the other variant (c.1101þ1G>T [GenBank:
NM_001005463.2] in EBF3 [MIM: 607407]) was a predicted loss-of-
function variant in a gene for which there is no known association
with disease. Neither of these two variants was relevant to this
analysis of classifying high-penetrance variants for Mendelian con-
ditions, for which the ACMG-AMP guidelines are intended. In addi-
tion, the two laboratories that had key personnel involved in the
development of the ACMG-AMP recommendations were excluded
from one study-wide sensitivity analysis to evaluate whether famil-
iarity with the system affects concordance. Lastly, we performed a
second sensitivity analysis by excluding the classifications of the
submitting laboratory to determine the dependence of these results
ona single laboratory andwhetherclassification ina real case setting
rather than only for the comparison study affects results.Analysis of ACMG-AMP Lines of Evidence
We analyzed the lines of evidence used for each variant classifi-
cation to identify how commonly specific evidence codes andThe Americclassification rules were used across all of the variants, the overall
agreement in the pattern of ACMG-AMP codes used across sites for
each variant, and the consistency with which each ACMG-AMP
code was used within each variant. These were determined with
a frequency table, the mean of coefficient of variation (CV) values
across variants with each ACMG-AMP code, and K-alpha values of
ACMG-AMP codes within each variant. Descriptive statistics of
how often the strength of each line of evidence was modified dur-
ing variant interpretation were also calculated.Consensus Discussions
The variants with discrepant classifications based on the ACMG-
AMP guidelines were discussed via phone conferences (n ¼ 23) or
via email (n ¼ 43). Variants were chosen for discussion by phone
conference if they were interpreted by all nine laboratories or if
they were discrepant by more than one category of disagreement.
The laboratory that submitted each of these 23 variants presented
the lines of evidence used by all laboratories and the rationale for
using, not using, or altering the strength of a particular evidence
code. Once all evidence was discussed, each laboratory was asked
to provide a final classification. For variants for which only one lab-
oratory was discordant for only a one-level difference, the discor-
dant laboratory was asked to re-review their classification in light
of the evidence used and classifications made by the other labora-
tories. The discordant laboratory then provided either a change
or adecision to retain theoriginal classification, including the ratio-
nale in both scenarios by email. During phone conferences and via
email, laboratories had the opportunity to share any internal data
that could have contributed to discordance.Results
Intra-laboratory Classification Concordance between
Unique Laboratory Criteria and the ACMG-AMP
System
The intra-laboratory comparison of the laboratory process
and the ACMG-AMP system for the 347 paired variant as-
sessments is summarized in Figure 1A. The classifications
matched for 275 of 347 (79%) variant assessments. Eleven
of the 347 paired variant assessments (3.2%) differed by
greater than one level. Overall, in 48 of the 72 (67%)
discordant calls, the ACMG-AMP system calls were closer
to VUS. Specifically, a classification of B or LB was more
likely to result from using the laboratories’ own criteria
than from using the ACMG-AMP criteria. The K-alpha
value for agreement within laboratories ranged from 0.77
to 1.00 (average ¼ 0.91; seven of nine laboratories had
K-alpha > 0.90).Inter-laboratory Concordance in Classification
Considering the inter-laboratory classification for 97 vari-
ants, there was no statistically significant difference in
concordance across laboratories between classifications
based on laboratory criteria and those based on ACMG-
AMP criteria (lab K-alpha ¼ 0.76, 95% CI ¼ [0.73, 0.80];
ACMG-AMP K-alpha ¼ 0.72, 95% CI ¼ [0.68, 0.76]). In
other words, implementation of the ACMG-AMP criteria
did not yield more consistent variant classification amongan Journal of Human Genetics 98, 1067–1076, June 2, 2016 1069
Figure 1. Distribution of Variant-Classification Comparisons according to the Extent of Differences across a Five-Tiered Classification
Scheme
(A) Intra-laboratory concordance between laboratory and ACMG-AMP classification systems. This graph compares each site’s use of the
ACMG-AMP rules to their own laboratory classification methods.
(B) Inter-laboratory concordance of 97 variants. This graph compares the same calls, based on either the ACMG-AMP rules or the site’s
rules, between laboratories.
(C) Inter-laboratory concordance after consensus efforts. This graph shows a final comparison of calls between sites after consensus-
building efforts.these laboratories. All laboratories reviewing the variant
(three to nine) agreed for 33 (34%) when they used either
the ACMG-AMP system or their own criteria. No signifi-
cant difference was found in inter-laboratory concordance
when the two laboratories that contributed to the ACMG-
AMP classification recommendations were removed from
the analysis (K-alpha lab ¼ 0.77, 95% CI ¼ [0.73, 0.80];
K-alpha ACMG-AMP ¼ 0.70, 95% CI ¼ [0.66, 0.74]) or
when the site that submitted the variant classifications
was removed from the analysis (K-alpha lab ¼ 0.76, 95%
CI ¼ [0.71, 0.80]; K-alpha ACMG-AMP ¼ 0.75, 95% CI ¼
[0.71, 0.78]). The distribution of types of disagreement
among laboratories using each method is shown in
Figure 1B. A total of 43/194 (22%) classifications had cate-
gory differences that are more likely to influence medical1070 The American Journal of Human Genetics 98, 1067–1076, Junedecision making (P or LP versus VUS, LB, or B), the major-
ity of which (33) were P or LP versus VUS. An additional 36
classifications (19%) involved differences between VUS
and LB or B, which could have an impact on results re-
ported by the laboratory given that many laboratories do
not report LB or B results and that reporting VUS results
could result in a more lengthy disclosure process and
uncertainty of follow-up. The remaining 25% of variant
classifications were differences in the confidence of calls
(P versus LP or B versus LB), which are unlikely to have
an impact on clinical care.
Consensus Discussions
The interpretation of 33/99 (34%) variants was identical
across all sites that used the ACMG-AMP guidelines. After2, 2016
Figure 2. Distribution of 99 Variants
Submitted for Assessment
Gray outlines illustrate the distribution of
variant classifications submitted for assess-
ment. Green bars indicate those calls that
were agreed upon after initial review, blue
bars indicate those calls agreed upon after
email exchange, and black bars indicate
those calls agreed upon after discussion
on conference calls.either emails or conference calls among the reporting
laboratories, consensus on variant classifications based
on the ACMG-AMP guidelines was achieved for 70/99
(71%) variants. Twenty-one of the discrepant variants
were resolved via email, and the remaining 16 were
resolved during phone conferences. The distribution and
sources of variant-interpretation consensus can be found
in Figure 2; gray outlines show the original distribution
of submitted variant interpretations. Figure 1C shows
the distribution of types of disagreement among labora-
tories after the consensus effort. Of the 29 variants that
remained discordant, 25 involved only one level of differ-
ence (15 differed in confidence differences, three differed
between LP and VUS, and seven differed between VUS
and LB). Of the four variants with greater than one level
of difference, two involved a difference between P and
VUS, LB, or B. The final classifications for the 70 variants
for which consensus was achieved, and the range of clas-
sifications for the remaining 29 discordant variants, are
presented in Table S1.
Consensus discussions led to the clarification of the
correct use of several ACMG-AMP lines of evidence,
some of which included errors in the appropriate use of
the rules already described in the guidelines (Table 1).
Although the ACMG-AMP guidelines suggest a VUS
classification when conflicting pathogenic and benign
lines of evidence are identified, some laboratories
allowed one line of conflicting benign evidence of only
a supporting level (e.g., computational predictions) to
override otherwise strong evidence of pathogenicity.
In these cases, consensus discussion led to the use of
expert judgment, as described in the ACMG-AMP
guidelines, for appropriately disregarding the limited
conflicting evidence, such as computational predic-
tions. For two variants, achieving concordant interpre-
tations required one laboratory’s internal data. It was
difficult to resolve the two variants that were excluded
from the intra- and inter-laboratory analyses because
the ACMG-AMP rules were not designed for low-pene-
trance variants (risk alleles) or variants in genes not
clearly associated with the disorder. Some discrepanciesThe American Journal of Human Gein classification occurred because
laboratories were interpreting the
same variant for two different
associated conditions, which have
different disease frequencies. Thisled to a discordant use of the rules related to allele
frequency.
Errors in Using the ACMG-AMP System
Our implementation of a computational tool to assess ac-
curacy of combining the ACMG evidence codes used by
the laboratories showed that for 16 out of 353 (5%) variant
assessments, the ACMG-AMP codes listed by the labora-
tories did not support the classification chosen. When
the laboratories were queried on these discrepancies, 9 of
the 16 were due to tabulation errors, whereas judgment
was used to override the ACMG-AMP rules for 7 of the 16
variants. The tabulation errors suggest that using computa-
tional tools to calculate the classification will lead to a
modest increase in the accuracy of applying the rules.
ACMG-AMP Lines of Evidence Invoked and Modified
in Strength
The frequency with which each ACMG-AMP code was
invoked is listed in Figure 3. All lines of evidence were
used at least once, except for BP7 (a silent, or synonymous,
variant) given that no silent variants were submitted.
Sixteen lines were used in fewer than 10% of variants,
seven were used in 11%–18% of variants, and four were
used in over 20% of all variant classifications: PVS1
(20%, predicted to be truncating), BS1 (26%, allele fre-
quency is too high), PP3 (39%, computational evidence),
and PM2 (41%, absent in population databases).
We further analyzed sources of discordance in the use of
the ACMG-AMP codes to identify those criteria commonly
used in an inconsistent manner. For variants where at least
one site invoked BA1 (the allele frequency is >5% and too
high to cause the disorder), we only evaluated concor-
dance of the use of BA1. This was due to the fact that if a
site selected BA1, they did not need to evaluate any other
codes. For rules invoked more than ten times overall, PP4
(the phenotype is highly specific to the gene) was used
the most inconsistently among the laboratories for a given
variant (mean CV ¼ 1.74). This is not surprising given the
subjective nature of deciding how specific a phenotype
is to a given gene. The most consistently applied rule wasnetics 98, 1067–1076, June 2, 2016 1071
Table 1. ACMG-AMP Rule Clarifications and Suggestions for Modification
Rule Description Clarifications and/or Suggestions
PVS1 variant predicted null where LOF is a mechanism of disease do not apply to variants that are near the 30 end of the gene and
escape nonsense-mediated decay
PS1 variant with the same amino acid change as a previously
established pathogenic variant, regardless of nucleotide
change
does not include the same variant being assessed because it is
not yet pathogenic, and the rule is intended for variants with a
different nucleotide change
PS2 de novo variant with confirmed maternity and paternity apply this rule asmoderate or supporting if the variant is mosaic and
its frequency in tissue is consistent with the phenotype
PS3 variant shown to have a deleterious effect by a well-established
functional study
reduce the strength for assays that are not as well validated or
linked to the phenotype
PM1 variant located in a mutational hotspot and/or critical and
well-established functional domain
not meant for truncations; more clarification is needed for
applying this rule
PM2, BS1 variant absent in population databases or with an allele
frequency too high for the disease
cannot assume longer indels would be detected by
next-generation sequencing
use a published control dataset if its size is at least 1,000 individuals
cannot be applied for low-quality calls or non-covered regions
must define the condition and inheritance pattern
PM3 for recessive disorders, variant in trans with a pathogenic variant invoke this rule as supporting if the phase is not established
can upgrade if more than one proband is reported
PM4 protein-length-changing variant applicable for in-frame deletions, insertions, or stop-loss variants,
but not frameshifts, nonsense, and splice variants
PM5 novel missense variant at amino acid with different
pathogenic missense change
ensure pathogenicity of previously reported variant
suggest changing ‘‘novel’’ to ‘‘different’’ because some variants that
are not novel might require assessment with this rule
PP3, BP4 variant with multiple lines of computational evidence all lines must agree
PP4 the patient’s phenotype or family history is highly specific to
the genotype
not meant to be used for genetically heterogeneous conditions
or conditions with unsolved etiology
not typically applied for an analysis of incidental findings, but it
could be applied for prior observations
PP5, BP6 variant called pathogenic or benign by a reputable source only applicable when evidence is not available (e.g., Sharing
Clinical Reports Project)
BS2 variant observed in a healthy adult for a disorder with full
penetrance at an early age
populations might not have been screened or excluded for the
phenotype
BP1 variant in a gene in which truncations primarily cause disease clarify the meaning of ‘‘primary’’; suggest >90%
BP2, BP5 variant in trans with a dominant pathogenic variant (BP2) or in
an individual with an alternate molecular basis for disease (BP5)
clarify that one should apply BP2 when the pathogenic variant
is seen in the same gene as the variant being evaluated and apply
BP5 when the pathogenic variant is in a different genePVS1 (null variant where loss of function [LOF] is a known
mechanism of disease; mean CV ¼ 0.55). The mean and
SD of the CV for all lines of evidence used are available
in Table S2.
We also evaluated which criteria laboratories had
increased or decreased in evidence strength and found
that a total of nine lines of evidence were modified at least
once. Three criteria were increased in strength (PM3, PP1,
and BP2), and seven were decreased in strength (PVS1,
PS1, PS2, PS3, PS4, PM3, and BS1). Co-segregation data
supporting pathogenicity (PP1) was the most commonly
modified line of evidence, whereby laboratories increased
the strength from supporting to moderate or strong for
nine interpretations on the basis of the strength of the
segregation evidence available in the literature or from1072 The American Journal of Human Genetics 98, 1067–1076, Junethe laboratory’s internal data. The other most common ex-
amples of modified strength included the following: PVS1
(a predicted null variant in a gene where LOF is a known
mechanism of disease) was downgraded from very strong
four times, PS2 (well-established functional studies show
a deleterious effect) was downgraded three times, and
BS1 (MAF is too high for the disorder) was downgraded
three times.
Specific Variant Examples
TheGLA (MIM: 300644) c.639þ919G>Avariant (GenBank:
NM_000169.2), which has been reported in individuals
with late-onset Fabry disease (MIM: 301500) and reduced
alpha-galactosidase A enzyme activity,18,19 was classi-
fied by three laboratories. Ranging from VUS to P, the2, 2016
Figure 3. Frequency of Use for Each ACMG Line of Evidenceinterpretations based on ACMG-AMP rules were discor-
dant; however, all sites agreed on the classification of P
when they used internal rules. This variant was absent
from 528 race-matched control individuals across two
studies.18–20 A functional study also supported an effect of
this variant on splicing.19 All three laboratories invoked
PS3 (a well-established functional study [clinical alpha-
galactosidase enzyme testing] showed a deleterious effect
of the variant) and PP1 (evidence of segregation), and one
site increased the strength of this line of evidence from sup-
porting to moderate on the basis of three families cited in
the literature. PS4 (the prevalence of the variant in affected
individuals is statistically greater than that in control indi-
viduals) was invoked by the one laboratory that called the
variant P by using both their own rules and the ACMG-
AMP criteria. Upon further discussion, the group agreed
that this rule was applicable on the basis of a single publica-
tion citing a significant p value and other studies showing a
statistical increase but requiring manual calculation. PVS1
(predicted-null variant in a gene where LOF is a known
mechanism of disease) was also applied by all three labora-
tories after the group decided to downgrade the strength
from very strong to strong because of the minor retention
of wild-type transcript and the fact that the variant was a
deep intronic variant for which a functional study was
needed to demonstrate its impact on splicing. Three lines
of evidence originally invoked by only one laboratory
each were discarded: (1) PM4 (protein-length-changing
variant) because this rule is only applicable for in-frame
deletions, insertions, and stop-loss variants; (2) PP5 (a repu-
table source calls the variant pathogenic) because the
reputable source’s evidence was available for review by the
curators and; (3) PP3 and BP4 (multiple lines of computa-
tional evidence agree) because this rule applies only when
all predictions agree and not simply when some agree and
others do not. All three sites came to a consensus that this
variant is P on the basis of both their internal laboratory
criteria and the ACMG-AMP criteria.
The group reviewed the c.1529C>T (p.Ala510Val) variant
(GenBank: NM_003119.2) in SPG7 (MIM: 602783), which
is associated with autosomal-recessive spastic paraplegia
(MIM: 607259), a disease that is known to have a variable,The Americbut generally adult, age of onset.21 It was interpreted by all
nine laboratories and had a range of pathogenicity classifica-
tions from LB to P. This variant was observed in 0.4% (267/
66,688) of chromosomes of European ancestry (EU) in the
ExAC Browser and has been found to have a 3%–4% hetero-
zygote frequency in the UK and an estimated homozygote
frequency of 20–40 per 100,000 individuals.22 Shared data
included that the variant was observed in the heterozygous
state in3of thefirst50participants sequencedby the submit-
ting laboratory’s CSER study. The frequency of SPG7-associ-
ated spastic paraplegia is conservatively estimated to be 2–6
per 100,000 individuals according to the higher estimate;
this yields an estimated frequency of 0.8% for all associated
alleles. Multiple publications have cited the identification
of homozygous or compound-heterozygous (including this
variant) affected individuals.22–24 It is notable that the labo-
ratories that concluded this was a VUS or LB variant consid-
ered the BS1 criteria (the variant is more common than the
disease, adjusted for the autosomal-recessive inheritance
pattern). Two of the laboratories that concluded the variant
was P according to the ACMG-AMP rules used the PM2
criteria (the variant is absent from control individuals or
has an extremely low frequency if recessive). The remainder
of the laboratories did not use any rules on population-fre-
quency data. An additional line of evidence with conflicting
use was PS1 (the variant results in the same amino acid
change as a previously established pathogenic variant,
regardless of nucleotide change). This rule was invoked
by four of nine laboratories; however, after clarification
that the intent of this rule, as described in the ACMG-AMP
guidelines, is to be applied only for a ‘‘different’’ nucleotide
change (i.e., something other than SPG7 c.1529C>T that
still leads to p.Ala510Val), all laboratories agreed that this
rule was not applicable. Consensus was not reached for
this variant largely because of discordance in applying
the population-frequency lines of evidence. Some groups
continued to weigh the published literature evidence of
pathogenicity, whereas other groups concluded that it
could not be a high-penetrance variant given its allele
frequency. Given a perceived deficit of affected homozy-
gotes relative to affected compound heterozygotes, some
felt it might have low penetrance unless it is pairedan Journal of Human Genetics 98, 1067–1076, June 2, 2016 1073
Box 1. Recommendations and Additional Resources for Increasing Consistency in the Usage of ACMG-AMP Rules
d Develop disease-specific allele-frequency thresholds to enable lowering of the stand-alone benign criteria from a
MAF of R5% to values specific to each disorder.
d Establish a resource of all genes to define whether LOF is a known mechanism of disease.
d Make recommendations for which computational algorithms are best in practice.
d Better define ‘‘well-established’’ functional data and/or distribute a resource that lists functional assays that meet
the well-established threshold. Also define when to use reduced strength of the rule.
d Develop quantitative thresholds of evidence for and against segregation of different strengths.
d Promote the development of software tools that automate computable aspects of the ACMG-AMP guidelines to
improve accurate use.with a more deleterious variant. Resolving the role of
this variant in disease might ultimately require a better un-
derstanding of the penetrance andpossible role ofmodifiers,
and classifying the pathogenicity of lower-penetrance vari-
ants was outside the scope of the ACMG-AMP guidelines.
The variant with the largest range of discordance (P to B)
after consensus efforts based on the ACMG-AMP guide-
lines was BTD (MIM: 609019) c.1330G>C (p.Asp444His)
(GenBank: NM_000060.2), which was interpreted by three
laboratories. BTD is associated with autosomal-recessive
biotinidase deficiency (MIM: 253260), and this variant
was detected in one allele of an unaffected individual.
The interpretations based on the ACMG-AMP guidelines
originally ranged from VUS to P; however, after consensus
efforts, the laboratory that classified the variant originally
as VUS changed their interpretation to B, whereas the other
two laboratories kept their interpretations as LP and P. This
variant has been identified in multiple biotinidase-defi-
ciency-affected individuals who have variants associated
with profound deficiency on the other allele.25,26 It was
observed in 5.4% of chromosomes of Finnish ancestry
and 4.15% of EU chromosomes in the ExAC Browser, and
there were 83 reported instances of homozygosity. The lab-
oratory that interpreted this variant as B invoked theMAF>
5% (BA1) as standalone criteria and noted the presence
of homozygotes in population databases. Like SPG7, this
might represent an allele that is more likely to be patho-
genic when it is found to be compound heterozygous
with a more deleterious allele than when it is found to be
homozygous. This is a general problem with recessive
disorders, and itmightmake consideration of the genotype
rather than the pathogenicity of each allelemore important
for disease prediction. The laboratories classifying this
variant as P and LP used expert judgment to overrule the
use of BA1, which supports a B classification. They cited
multiple reputable laboratories that have interpreted this
variant as pathogenic and evidence that individuals who
are homozygous and compound heterozygous for this
variant might have a more mild form of the disease.
Consensus efforts brought the group further from agree-
ment on this variant; however, this highlights the impor-
tance of employing expert judgment when making inter-
pretations, as well as the challenges that stem from using1074 The American Journal of Human Genetics 98, 1067–1076, Junethe ACMG-AMP guidelines to interpret the clinical signifi-
cance of variants that might be associated with lower pene-
trance and mild presentations of disease.
The Supplemental Note and Table 1 describe in detail the
criteria-specific clarifications that resulted from common
usage errors, as well as the challenges and discussion topics
related to each of the ACMG-AMP evidence categories that
are utilized in implementing the ACMG-AMP guidelines.
This material is designed to further clarify numerous rules
found in the ACMG-AMP publication. In addition, more
general recommendations and additional resources that
could increase consistency of the usage of ACMG-AMP
rules across laboratories are defined in Box 1.Discussion
Interpreting the pathogenicity of a genetic variant requires
evaluating a large number of heterogeneous types of
evidence to arrive at a unitary descriptor of pathoge-
nicity. Given the complexity of the data and uncertainty
regarding the validity or utility of some of the data used
for these interpretations, it is unsurprising that there
would be variation among laboratories regarding these de-
terminations. To that end, the ACMG-AMP system for clas-
sifying variant pathogenicity10 is an important first step in
efforts to improve the consistency of variant classification
among laboratories. The guidelines include standardized
terminology for classifying variants associated with mono-
genic diseases and a defined series of evidence types that
can be used in pathogenicity assessment, enabling a record
of the specific evidence type and strength used for deter-
mining pathogenicity. This enhances transparency and
facilitates resolution of discrepancies in variant interpreta-
tion. It also forms a basis for iteratively building on the
evidence as new data become available over time.
This study systematically evaluated the implementation
of the ACMG-AMP guidelines in the medical practice of
variant assessment.Nearly all ACMG-AMP lines of evidence
were used, and PVS1 (predicted truncating), BS1 (allele
frequency too high), PP3 (computational evidence), and
PM2 (absent in population databases) (Figure 3) reflect the
spectrum of variants chosen for the exercise and the most2, 2016
available types of data. We identified differences in the
application of the criteria but no difference in classification
concordance between the ACMG-AMP system and the lab-
oratory method. In part, the discordance in applying the
ACMG-AMP guidelines was due to the subjective process
of deciding when certain criteria are met. However, the
guidelines provided a valuable framework for subsequent
discussion of evidence, often leading to resolution of differ-
ences in variant interpretation; achieving this would have
beenmore difficult if each laboratory relied on an indepen-
dent method for variant assessment. The differences in
both the intra- and inter-laboratory analyses identified
points of confusion and inaccurate use of the ACMG-AMP
criteria, as well as areas where expert judgment is required
and additional guidance is needed. It should be noted that
this was the first time that most sites had worked with the
ACMG-AMP guidelines, and thus familiarity and systems
for implementation of the criteria were still evolving. In
addition, because the variants were distributed as a pilot
evaluation of the ACMG-AMP guidelines and not for clin-
ical reporting, not all sites subjected the variants to their
typical CLIA process of review, which includes final review
by a board-certified laboratory geneticist or an equivalently
trained individual. Thus, the level of discordance reported
heremight have been inflated by the atypical workflows be-
ing deployed. In contrast, the resolution of the discordant
variants involved multiple board-certified geneticists and
others with long-standing experience in variant assess-
ment, documenting the importance of this level of training
invariant interpretation. These study results underscore the
need for training in the use of genetic resources, evaluation
of variant evidence, and application of the ACMG-AMP
guidelines, even among experienced professionals. This
study identified areas of confusion regarding the ACMG-
AMP criteria, and thesewill be useful in developing training
materials and further guidance for variant assessment.
As recently described,3 the Clinical Genome Resource
(ClinGen) consortium is developing tools to aid variant
classification based on the ACMG-AMP guidelines and
will make this information public through both commu-
nity availability of the tool and documentation of applied
codes with variants submitted to ClinVar.
As described above, our discussion and consensus build-
ing led to a decrease in variant discordance from 66% to
29% of the 99 variants analyzed. This underscores the
importance of not only having a standardized approach
to variant assessment but also sharing variant interpreta-
tions for identifying and potentially resolving discordance.
Given the rarity of most variants causative for monogenic
disease, sharing data and comparing interpretations are
imperative for ensuring the greatest opportunity for
informed and collaborative variant interpretation. It is
important to also reflect on the goals of variant assessment.
Although numerous variants have robust evidence that
can unequivocally allow classification into discreet cate-
gories without debate, many other variants have limited
or conflicting evidence, making it difficult to accuratelyThe Americclassify these variants. Indeed, for 29 (29%) of the 99
variants assessed in this study, a consensus classification
was not achieved, and 5 of the 29 involved a difference
between the categories of P or LP and VUS, LB, or B, which
could affect medical management. This finding high-
lights that classifying sequence variants is similar to other
fields of medicine in which practitioners can legitimately
differ in their assessments of pathogenicity of a laboratory
finding. By defining and applying formal criteria that parse
these heterogeneous data types, we can better understand
and analyze these legitimate differences in expert opinion
and at the same time reduce errors and discrepancies.Supplemental Data
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